| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Sugar AM | |
| P2860 | cites work | A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group | Q68062081 |
| The effects of azole and polyene antifungals on the plasma membrane enzymes of Candida albicans | Q69819279 | ||
| Correlation of in Vitro Susceptibility Test Results with in Vivo Response: Flucytosine Therapy in a Systemic Candidiasis Model | Q70257684 | ||
| Histoplasmosis in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and fluconazole | Q70459467 | ||
| In vitro veritas? Antimicrobial susceptibility tests and their clinical relevance | Q70946866 | ||
| Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients | Q72430003 | ||
| Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism | Q72740939 | ||
| A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute | Q72741418 | ||
| Combination therapy in experimental invasive aspergillosis | Q72888278 | ||
| Antifungal Action of Amphotericin B in Combination with Other Polyene or Imidazole Antibiotics | Q72940802 | ||
| Saperconazole therapy of murine disseminated candidiasis: efficacy and interactions with amphotericin B | Q24616032 | ||
| Overview of medically important antifungal azole derivatives | Q24617248 | ||
| Treatment of murine cryptococcal meningitis with an SCH 39304-amphotericin B combination | Q28333963 | ||
| Treatment of disseminated Torulopsis glabrata infection with DO870 and amphotericin B. | Q33755079 | ||
| Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole | Q33758350 | ||
| Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group | Q35110598 | ||
| Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. | Q35112132 | ||
| Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. | Q35900199 | ||
| Current role of therapy with amphotericin B | Q35997102 | ||
| Interactions of amphotericin B and SCH 39304 in the treatment of experimental murine candidiasis: lack of antagonism of a polyene-azole combination | Q36754603 | ||
| Direct membrane-damaging effect of ketoconazole and tioconazole on Candida albicans demonstrated by bioluminescent assay of ATP | Q39848887 | ||
| Primary site of action of ketoconazole on Candida albicans | Q39857229 | ||
| Effect of ketoconazole on isolated mitochondria from Candida albicans | Q39857233 | ||
| Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum | Q39867085 | ||
| Antifungal susceptibility testing | Q40795131 | ||
| Oral azole drugs as systemic antifungal therapy | Q40796244 | ||
| In vitro studies of amphotericin B in combination with the imidazole antifungal compounds clotrimazole and miconazole | Q40957348 | ||
| A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis | Q41644134 | ||
| Correlation between in vitro and in vivo activity of antifungal agents against Candida species | Q42283580 | ||
| Interactions in vitro between polyenes and imidazoles against yeasts | Q43752639 | ||
| Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice | Q43805413 | ||
| Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance | Q44986554 | ||
| The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis | Q45179704 | ||
| Effects of 1-(Halogenalkoxy)Alkyl-5-Fluorouracil Derivatives on Cell Growth, Cell Volume and Nucleus Size of Mouse Lymphoma Cells | Q47418595 | ||
| Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. | Q54215184 | ||
| Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. | Q54393212 | ||
| The interaction of miconazole and ketoconazole with lipids | Q67232012 | ||
| Combination therapy in a model of pulmonary aspergillosis | Q67876510 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | amphotericin B | Q412223 |
| P304 | page(s) | 1907-1912 | |
| P577 | publication date | 1995-09-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Use of amphotericin B with azole antifungal drugs: what are we doing? | |
| P478 | volume | 39 |
| Q44440960 | A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. |
| Q46421810 | Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients |
| Q54394711 | An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. |
| Q40900121 | Antifungal agents in the 1990s. Current status and future developments |
| Q33539956 | Antifungal and antiviral agents: a review |
| Q36201569 | Antifungal combination therapy: clinical potential |
| Q80098602 | Antifungal combination therapy: where we stand |
| Q40878512 | Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches |
| Q33693370 | Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model |
| Q42409788 | Challenges in designing animal studies to detect antagonism of polyene activity |
| Q46460310 | Clinical experience in managing Fusarium solani keratitis |
| Q33721804 | Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. |
| Q76381447 | Combination antifungal therapy |
| Q36895652 | Combination antifungal therapy: the new frontier |
| Q37204192 | Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis |
| Q35136738 | Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. |
| Q35628245 | Comparative effectiveness of induction therapy for human immunodeficiency virus-associated cryptococcal meningitis: a network meta-analysis |
| Q46039199 | Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp. |
| Q24550733 | Current and emerging azole antifungal agents |
| Q44440963 | Editorial Commentary: Fluconazole Plus Amphotericin B Combinations Are Not Contraindicated and May Add Benefit for the Treatment of Candidemia |
| Q36290748 | Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae |
| Q34382518 | Eradication of severe neonatal systemic candidiasis with amphotericin B lipid complex |
| Q34883912 | Flucytosine-fluconazole cross-resistance in purine-cytosine permease-deficient Candida lusitaniae clinical isolates: indirect evidence of a fluconazole uptake transporter |
| Q73074989 | Fungal infections of the central nervous system |
| Q33961800 | Fungal resistance |
| Q40098450 | Gastro-intestinal basidiobolomycosis in a 2-year-old boy: dramatic response to potassium iodide. |
| Q35128918 | In vitro interaction between amphotericin B and azoles in Candida albicans. |
| Q53727517 | In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: effect of concentration and exposure time. |
| Q38855286 | In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs |
| Q33803508 | Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo |
| Q33980497 | Interactions between triazoles and amphotericin B against Cryptococcus neoformans |
| Q28362562 | Interactions of posaconazole and flucytosine against Cryptococcus neoformans |
| Q35109119 | Invasive oesophageal candidiasis: current and developing treatment options |
| Q77805823 | Invasive sinus aspergillosis in apparently immunocompetent hosts |
| Q46448567 | Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis |
| Q34143326 | Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. |
| Q35105394 | Itraconazole--perspectives for the management of invasive aspergillosis |
| Q39475550 | Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy |
| Q41377981 | Key issues concerning fungistatic versus fungicidal drugs |
| Q34071597 | New antifungal agents and preparations |
| Q35561985 | New approaches to invasive fungal infections |
| Q35220799 | Novel antifungal drugs against fungal pathogens: do they provide promising results for treatment? |
| Q35756513 | Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination |
| Q44909800 | Pediatric coccidioidomycosis in central California: a retrospective case series |
| Q90045315 | Synergistic antifungal interactions of amphotericin B with 4-(5-methyl-1,3,4-thiadiazole-2-yl) benzene-1,3-diol |
| Q34344425 | Systemic antifungal agents. |
| Q73339231 | Systemic candidiasis in cardiac surgery patients |
| Q33760507 | The past, present and future of antimycotic combination therapy |
| Q35828187 | Toward more effective antifungal therapy: the prospects of combination therapy. |
| Q41188065 | Update on invasive candidiasis |
Search more.